Guardant Health Stock
Guardant Health, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Helmy Eltoukhy
- Employees
- 2,498
- Market cap
- $21.3 B
- IPO
- 04/10/2018
Guardant Health, Inc., headquartered in Palo Alto, USA, is a precision oncology company operating within the Healthcare sector. Established in 2011, the company delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Guardant Health stock: price history
1D
-4.4%
1W
-5.3%
1M
-9.3%
6M
+75.5%
YTD
+55.3%
1Y
+135.1%
2Y
+633.6%
5Y
+56.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~46% stronger price swings than usual
Guardant Health stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Guardant Health is a specialized precision oncology company offering a range of diagnostic blood tests based on liquid biopsy technology. Its portfolio includes Guardant360 and GuardantOMNI, as well as the research platform GuardantINFORM, which is built on extensive clinical-genomic datasets. Beyond patient diagnostics, the company provides services to biopharmaceutical stakeholders, including companion diagnostics, clinical trials support, and test development. The business model encompasses both the provision of diagnostic tests and specialized research and software solutions.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Weak
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Guardant Health
Analyst assessment of Guardant Health
PRICE TARGET LOW
US$180.00
CONSENSUS
US$202.40
MEDIAN
US$200.00
PRICE TARGET HIGH
US$225.00
0
STRONG BUY
30
BUY
0
HOLD
1
SELL
0
STRONG SELL
31
TOTAL · Buy
As of: 13/10/2026
Guardant Health stock metrics
P/E
-45.44
P/B
-93.99
EV/EBITDA
-53.33
RETURN ON EQUITY
53.9%
NET MARGIN
-35.9%
DEBT/EQUITY
-7.61
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.0%
FLOAT SHARES
128,764,014
AVG. DAILY VOLUME (30D)
1,820,508
Insider transactions (SEC)
Azar Alex M II
Azar Alex M II
Eltoukhy Helmy
Chudova Darya
Chudova Darya
Attention
1 mention today in US forums, 50% fewer than yesterdayPrice since yesterday: -4.4%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about Guardant Health stock
What does Guardant Health do?
Guardant Health, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Helmy Eltoukhy, the company employs around 2,498 people.
The IPO was on 04/10/2018; the stock trades on NASDAQ under the ticker GH.
What do analysts say about Guardant Health stock?
31 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$202.40, ranging from US$180.00 to US$225.00, with a median of US$200.00.
This is an external assessment, not a statement by Market Jury.
When does Guardant Health report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 46% stronger than usual.
Does Guardant Health pay a dividend?
No, Guardant Health currently does not pay a dividend.
Which stocks are comparable to Guardant Health?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Guardant Health stock analyzed?
Clicking "Analyze stock" lets five strategies assess Guardant Health against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.